| [1] |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108.
|
| [2] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
| [3] |
Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity[J]. Surg Oncol, 2011, 104(6): 692-8.
|
| [4] |
Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges[J]. Expert Rev Anticancer Ther, 2007, 7(10): 1369-78.
|
| [5] |
Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives[J]. Future Oncol, 2010, 6(4): 527-37.
|
| [6] |
Silden E, Hjelle SM, Wergeland L, et al. Expression of TP53 isoforms p53beta or p53gamma enhances chemosensitivity in TP53(null) cell lines[J]. PLoS One, 2013, 8(2): e56276.
|
| [7] |
Marcel V, Fernandes K, Terrier O, et al. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response[J]. Cell Death Differ, 2014, 21(9): 13 77-87.
|
| [8] |
Li M, Xu T, Zhang Z, et al. Phase Ⅱ multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-α in combination with chemotherapies in cancer patients[J]. Cancer Sci, 2012, 103(2): 288-95.
|
| [9] |
Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders[J]. J Clin Invest, 2001, 107(3): 24 7-54.
|
| [10] |
Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily[J]. Biochem Phramacol, 2003, 66(8): 1403-8.
|
| [11] |
Wang Y, Wang X, Zhao H, et al. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NFkappaB activation and Bcl-2 overexpression[J]. J Chemother, 20 12, 24(6): 348-57.
|
| [12] |
el-Deiry WS, Kern SE, Pietenpol JA, et al. Definition of a consensus binding site for p53[J]. Nat Genet, 1992, 1(1): 45-9.
|
| [13] |
Bourdon JC, Deguin-Chambon V, Lelong JC, et al. Further characterisation of the p53 responsive element: identification of new candidate genes for trans-activation by p53[J]. Oncogene, 19 97, 14(1): 85-94.
|
| [14] |
Ju WK, Lindsey JD, Angert M, et al. Glutamate receptor activation triggers OPA1 release and induces apoptotic cell death in ischemic rat retina[J]. Mol Vis, 2008, 14: 2629-38.
|
| [15] |
Lane D, Levine A. p53 research: the past thirty years and the next thirty years[J]. Cold Spring Harb Perspect Biol, 2010, 2(12): a000893.
|
| [16] |
Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity[J]. Genes Dev, 20 05, 19(18): 2122-37.
|
| [17] |
Khoury MP, Bourdon JC. p53 isoforms: an intracellular microprocessor?[J]. Genes Cancer, 2011, 2(4): 453-65.
|
| [18] |
Avery-Kiejda KA, Morten B, Wong-Brown MW, et al. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome[J]. Carcinogenesis, 2014, 35 (3): 586-96.
|
| [19] |
Marcel V, Dichtel-Danjoy ML, Sagne C, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models[J] .Cell Death Differ, 2011, 18 (12): 1815-24.
|
| [20] |
Tanabe K, Kim R, Inoue H, et al. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs[J]. Int J Oncol, 2003, 22(4): 87 5-81.
|
下载:
